SARS CoV 2 News and Research

RSS

First clinical trial in South Africa for Covid-19 vaccine begins

The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

23 Jun 2020

Study confirms higher rates of positive COVID-19 cases in Latinx populations

In a new analysis of SARS-CoV-2, the virus that causes COVID-19, test results for nearly 38,000 people has found a positivity rate among Latinx populations about three times higher than for any other racial and ethnic group.

23 Jun 2020

Nicoya receives NRC IRAP funding to develop saliva-based diagnostic test for COVID-19

Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, will receive advisory services and up to $299,190 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program to develop a portable COVID-19 diagnostic test called Atlas.

From Nicoya Lifesciences 23 Jun 2020

Lehigh University receives funding to create functional material that kills coronavirus

Lehigh is one of four universities to receive funding through the Manufacturing PA Innovation Program COVID-19 Challenge supporting innovative research projects that could potentially impact Pennsylvania's pandemic response.

23 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020

Scientists find COVID-19 antibodies fade quickly

Now, a new study shows that the levels of antibodies found in recovered coronavirus disease (COVID-19) patients declined sharply in just two to three months after infection for both symptomatic and asymptomatic patients.

23 Jun 2020

Scientists create 'all-atom' model of SARS-CoV-2 spike protein

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease (COVID-19), an illness that has spread across the globe, infecting more than 9 million people. The novel coronavirus invades cells through "spike proteins," which sticks and binds itself to a host cell.

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Colombian corona hounds: SAR-CoV-2 detection by dogs

A new Colombian study published on the preprint server bioRxiv in June 2020 describes the use of trained dogs to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected humans by scent alone. This would allow uninfected people to work together safely, rescuing the economy without driving up medical costs.

23 Jun 2020

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Dire warning on contamination of water and COVID-19 spread

A recent report by scientists in the United Kingdom and Poland and published on the preprint server medRxiv in June 2020 describes the presence of stable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in water for up to 25 days, with the risk of infection by the contaminated water varying by the country’s environment.

22 Jun 2020

Prior infection provides protection against SARS-CoV-2 virus in hamsters

In an animal model for COVID-19 that shares important features of human disease, scientists at the University of Wisconsin–Madison, the University of Tokyo and the Icahn School of Medicine at Mount Sinai show that prior infection with the SARS-CoV-2 virus provides protection against reinfection, and treatment with convalescent serum limits virus replication in their lungs.

22 Jun 2020

New insights on antibody testing and RNA testing for SARS-CoV-2

Two types of tests are used to track SARS-CoV-2. Reverse transcriptase PCR (rt-PCR) tests for current infection. Antibody tests reveal that an infection has taken place, even long after the fact.

22 Jun 2020

SARS-CoV-2 paradox: Lower death rate during early stages of the pandemic

An analysis of national weekly mortality rates between December 2019 - March 2020, compared to the same period for the previous five years, by researchers at WMG and WMS, University of Warwick, has shown that there have been fewer deaths registered this year during the lead up to the Covid-19 pandemic.

22 Jun 2020

Three vaccine candidates race to combat SARS-CoV-2

As the coronavirus disease (COVID-19) ravages across the globe, scientists are racing to develop an effective vaccine to combat the viral infection. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease has infected nearly 9 million people.

22 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Maintaining social distancing and using face masks could help avoid a second COVID-19 wave

Individual behavior has a significant effect on preventing a large second wave of COVID-19 infections. In fact, maintaining social distancing and other interventions such as the use of face masks and hand hygiene could remove the need for future lockdowns, according to a modeling study performed by the Barcelona Institute for Global Health, an institution supported by the "la Caixa" Foundation.

22 Jun 2020